{"denomUnitsSelected":"Participants","description":"Progression Free Survival (PFS) based upon investigator assessment of progression between patients in the two treatment arms in the subset of patients with tumors bearing a PIK3CA mutation.","reportingStatus":"NOT_POSTED","timeFrame":"Day 1, Cycle 1, Day 1, Cycle 4, End of Treatment, approx 24 months","title":"PIK3CA Genotype Assessed in Circulating cfDNA","type":"OTHER_PRE_SPECIFIED"}